Temporary Interruption of Endocrine Therapy for Breast Cancer Safe
THURSDAY, May 4, 2023 (HealthDay News) -- Among select women with previous hormone receptor-positive early breast cancer, there is no increase in the short-term risk for breast cancer events with temporary interruption of endocrine therapy to attempt pregnancy, according to a study published in the May 4 issue of the New England Journal of Medicine.
Ann H. Partridge, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues examined the temporary interruption of adjuvant endocrine therapy to attempt pregnancy in young women with previous breast cancer (aged 42 years or younger). A total of 516 participants had had stage I, II, or III disease (93.4 percent stage I or II), received adjuvant endocrine therapy for 18 to 30 months, and desired pregnancy. Overall, 497 women were followed for pregnancy status.
The researchers found that 74.0 percent of the women had at least one pregnancy and 63.8 percent had at least one live birth. Overall, 365 babies were born. Forty-four patients had a breast cancer event at 1,638 patient-years of follow-up (median follow-up, 41 months); this did not exceed the prespecified safety threshold of 46 breast cancer events. The three-year incidence of breast cancer events was 8.9 and 9.2 percent in the treatment-interruption and control cohorts, respectively.
"The POSITIVE trial provides prospective data showing that the temporary interruption of endocrine therapy to attempt pregnancy after hormone receptor-positive early breast cancer does not appear to increase the risk of recurrence or of contralateral breast cancer in the subsequent three years," write the authors of an accompanying editorial. "Physicians should now incorporate these positive data into their shared decision-making process with patients."
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Mente y cuerpo: el matrimonio y vivir en la ciudad podrían ayudar en la enfermedad cardiaca
MIÉRCOLES, 1 de septiembre de 2021 (HealthDay News) -- Los sentimientos de...
Telmisartan Linked to Reduced Risk for Alzheimer Disease in Black Patients
MONDAY, Nov. 7, 2022 (HealthDay News) -- In African American patients,...
Inequalities in Human Resources for Health Linked to Mortality
MONDAY, May 15, 2023 (HealthDay News) -- Inequalities in human resources for...
U.S. Orders 105 Million More Pfizer Shots for Fall Booster Campaign
THURSDAY, June 30, 2022 (HealthDay News) -- Anticipating a surge in booster...